Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.
Cancer|January 21, 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter studyAlessandra Iurlo, Daniele Cattaneo, Carmen Fava, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Cancer|June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML CampusValentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.
Frontiers in Oncology|September 13, 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA NetworkGiorgina Specchia, Patrizia Pregno, Massimo Breccia, et al.
British Journal of Haematology|October 12, 2021
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML reportMassimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Oncotarget|September 1, 2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Alessandro Nobili, Roberto Latagliata, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
Cancer Medicine|February 17, 2021
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA studyMichele Malagola, Alessandra Iurlo, Elisabetta Abruzzese, et al.
Cancer|January 21, 2026
Second attempt to discontinue TKI after molecular relapse in patients with chronic myeloid leukemia: A real-life Italian multicenter studyAlessandra Iurlo, Daniele Cattaneo, Carmen Fava, et al.
Blood|June 28, 2013
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013Michele Baccarani, Michael W Deininger, Gianantonio Rosti, et al.
Haematologica|March 2, 2019
Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practiceCarmen Fava, Giovanna Rege-Cambrin, Irene Dogliotti, et al.
Annals of Hematology|August 9, 2019
Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontlineMonica Crugnola, Fausto Castagnetti, Massimo Breccia, et al.
Leukemia|July 11, 2025
2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemiaJane F Apperley, Dragana Milojkovic, Nicholas C P Cross, et al.
Cancer|June 29, 2025
Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML CampusValentina Giai, Tiziana Rosso, Fausto Castagnetti, et al.
Frontiers in Oncology|September 13, 2021
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA NetworkGiorgina Specchia, Patrizia Pregno, Massimo Breccia, et al.
British Journal of Haematology|October 12, 2021
COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML reportMassimo Breccia, Elisabetta Abruzzese, Vincenzo Accurso, et al.
Oncotarget|September 1, 2016
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcomeAlessandra Iurlo, Alessandro Nobili, Roberto Latagliata, et al.
Pageof 16